Zacks: Analysts Expect Incyte Co. (INCY) Will Announce Earnings of -$0.48 Per Share

Wall Street analysts expect Incyte Co. (NASDAQ:INCY) to report earnings of ($0.48) per share for the current fiscal quarter, according to Zacks Investment Research. Twenty analysts have provided estimates for Incyte’s earnings, with the lowest EPS estimate coming in at ($0.68) and the highest estimate coming in at $0.22. Incyte posted earnings per share of $0.15 in the same quarter last year, which would indicate a negative year over year growth rate of 420%. The company is expected to announce its next quarterly earnings report on Tuesday, February 13th.

On average, analysts expect that Incyte will report full year earnings of ($1.33) per share for the current fiscal year, with EPS estimates ranging from ($1.49) to ($0.66). For the next financial year, analysts expect that the company will post earnings of $0.18 per share, with EPS estimates ranging from ($1.83) to $1.98. Zacks’ EPS calculations are an average based on a survey of research firms that follow Incyte.

Incyte (NASDAQ:INCY) last announced its quarterly earnings results on Tuesday, October 31st. The biopharmaceutical company reported $0.17 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.06 by $0.11. Incyte had a negative return on equity of 12.91% and a negative net margin of 10.90%. The business had revenue of $381.50 million during the quarter, compared to the consensus estimate of $360.34 million. During the same quarter in the prior year, the company posted $0.19 earnings per share. Incyte’s revenue was up 41.6% compared to the same quarter last year.

Several brokerages recently issued reports on INCY. BMO Capital Markets reiterated an “outperform” rating and set a $163.00 price target (down previously from $172.00) on shares of Incyte in a report on Monday, September 11th. Raymond James Financial reiterated a “buy” rating on shares of Incyte in a report on Tuesday, December 12th. Oppenheimer reiterated a “hold” rating and set a $135.00 price target on shares of Incyte in a report on Sunday, September 10th. Goldman Sachs Group began coverage on Incyte in a report on Friday, October 6th. They set a “buy” rating and a $160.00 price target for the company. Finally, ValuEngine downgraded Incyte from a “hold” rating to a “sell” rating in a report on Wednesday, November 29th. One investment analyst has rated the stock with a sell rating, seven have issued a hold rating, seventeen have issued a buy rating and one has assigned a strong buy rating to the company. Incyte presently has a consensus rating of “Buy” and an average target price of $143.84.

In other news, insider David W. Gryska sold 3,915 shares of the company’s stock in a transaction on Thursday, November 2nd. The stock was sold at an average price of $105.63, for a total transaction of $413,541.45. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, EVP Reid M. Huber sold 696 shares of the company’s stock in a transaction on Friday, December 1st. The shares were sold at an average price of $98.01, for a total value of $68,214.96. The disclosure for this sale can be found here. Insiders have sold a total of 33,118 shares of company stock worth $3,481,833 in the last ninety days. Insiders own 17.70% of the company’s stock.

Several hedge funds and other institutional investors have recently modified their holdings of INCY. Vanguard Group Inc. lifted its position in shares of Incyte by 11.1% during the 2nd quarter. Vanguard Group Inc. now owns 17,125,542 shares of the biopharmaceutical company’s stock valued at $2,156,276,000 after buying an additional 1,709,685 shares during the last quarter. Manning & Napier Advisors LLC purchased a new position in shares of Incyte during the 3rd quarter valued at $125,065,000. Janus Henderson Group PLC lifted its position in shares of Incyte by 4,570.1% during the 2nd quarter. Janus Henderson Group PLC now owns 1,045,363 shares of the biopharmaceutical company’s stock valued at $131,622,000 after buying an additional 1,022,979 shares during the last quarter. Old Mutual Global Investors UK Ltd. lifted its position in shares of Incyte by 374.4% during the 3rd quarter. Old Mutual Global Investors UK Ltd. now owns 930,319 shares of the biopharmaceutical company’s stock valued at $108,605,000 after buying an additional 734,235 shares during the last quarter. Finally, Matrix Capital Management Company LP lifted its position in shares of Incyte by 28.3% during the 2nd quarter. Matrix Capital Management Company LP now owns 1,796,716 shares of the biopharmaceutical company’s stock valued at $226,225,000 after buying an additional 396,716 shares during the last quarter. 90.74% of the stock is currently owned by hedge funds and other institutional investors.

Shares of Incyte (NASDAQ:INCY) traded down $0.67 during trading on Friday, reaching $94.71. The company had a trading volume of 1,236,807 shares, compared to its average volume of 1,304,856. Incyte has a 1-year low of $92.91 and a 1-year high of $153.15. The company has a market capitalization of $20,128.74, a P/E ratio of -118.39 and a beta of 0.74. The company has a debt-to-equity ratio of 0.01, a current ratio of 4.82 and a quick ratio of 4.81.

TRADEMARK VIOLATION NOTICE: “Zacks: Analysts Expect Incyte Co. (INCY) Will Announce Earnings of -$0.48 Per Share” was originally posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this piece on another site, it was illegally copied and republished in violation of United States and international copyright & trademark law. The correct version of this piece can be viewed at https://www.dispatchtribunal.com/2018/01/14/zacks-analysts-expect-incyte-co-incy-will-announce-earnings-of-0-48-per-share.html.

About Incyte

Incyte Corporation is a biopharmaceutical company focused on the discovery, development and commercialization of therapeutics. Its portfolio includes compounds in various stages, ranging from preclinical to late-stage development, and commercialized products, such as JAKAFI (ruxolitinib) and ICLUSIG (ponatinib).

Get a free copy of the Zacks research report on Incyte (INCY)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Incyte (NASDAQ:INCY)

Receive News & Ratings for Incyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Incyte and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply